Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We need human blood to understand the immune response to infection and to test promising new vaccines against infectious diseases in the laboratory. One test is called the Serum Bactericidal Assay (or SBA), which is measure of how effective antibodies are at killing certain bacteria and can be an important measure of how effective a new vaccine may be.

The samples would be used in the laboratory analysis of clinical trials of vaccines used in adults and children, and some samples in pre-clinical (animal) experiments testing new vaccines before they enter human-stage testing. Most people have some form of protection against most bacteria already, so not everyone is a suitable blood donor for this laboratory test. We therefore start by taking a small blood sample and test this one before asking for more blood if we found yours suitable for the work we do.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Immunity Assessment

NCT05080231

COVID-19

COMPLETED

Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development

NCT00401232

Healthy Subjects

COMPLETED NA

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

NCT05338762

SARS-CoV2 Infection

COMPLETED

Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.

NCT04954937

Healthy

UNKNOWN

SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study

NCT05492227

COVID-19 Coronavirus Disease 2019 COVID-19 Pandemic +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complement Mediated Bacterial Killing in Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy adults

Healthy adults aged 18 to 70 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to give informed consent for participation in the study
* Aged between 18 and 70 years
* In good health as determined by medical history and clinical judgment of the Investigators
* Able to attend the scheduled visits and to comply with all study procedures
* If found to be a suitable complement that they are willing to be approached for further donations

Exclusion Criteria

* Body weight less than 50kgs
* Have any known or suspected impairment or alteration of immune function, resulting from, as examples:congenital or acquired immunodeficiency, receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy, receipt of immunoglobulin or any blood product transfusion within the last 3 months
* Female participants who are pregnant
* Any chronic illness that could, in the opinion of the Investigators, interfere with immune function or with the donation of large volumes of blood (e.g. thrombocytopaenia or coagulopathy, malabsorption disorders, chronic anaemia)
* An individual who is on the delegation log for the study
* Planned blood donation within 4 months of undergoing testing to assess whether the individual is a suitable Complement donor

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes